ASAH1 and breast cancer: In addition, either ASAH1 overexpression or stimulation with activator S1P was sufficient to reverse the expression of cyclin protein inhibited by MCL treatment in TAMR‐BC cells (Figure 4H), which precisely verified our hypothesis that ASAH1 might be a potential major regulatory target of MCL.